Bolt Biotherapeutics Presents Preclinical Data Showing Eradication of Large Resistant Tumors with ISAC Monotherapy at SITC 2019

By In The News
November 9, 2019 in The Headlines

Recommended Posts

In The News

Posted November 9, 2019

- Share

Posted November 9, 2019

REDWOOD CITY, Calif., Nov. 9, 2019 /PRNewswire/ -- Bolt Biotherapeutics, Inc., a private biotechnology company focused on using its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to unleash the power of the immune system to treat cancer, today reported new preclinical...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  219773
2. Jaydee
  16652
3. Kip Powick
  12202
4. deicer
  12156
5. dagger
  9595
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  270k
- Total Posts
  
  558.3k

Sign In

Bolt Biotherapeutics Presents Preclinical Data Showing Eradication of Large Resistant Tumors with ISAC Monotherapy at SITC 2019

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support